A SUR1/Kir6.2 channel inhibitor
Related Products
Active Metabolite(s)
100085204-hydroxy Tolbutamide
Labeled Version(s)
30738Tolbutamide-d9
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Tolbutamide

Item No. 19888

Technical Information
Formal Name
N-[(butylamino)carbonyl]-4-methyl-benzenesulfonamide
CAS Number
64-77-7
Synonyms
  • D 860
  • NSC 23813
  • NSC 87833
  • U-2043
Molecular Formula
C12H18N2O3S
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 30 mg/mlEthanol:PBS (pH 7.2) (1:6): 0.14 mg/ml
λmax
229 nm
SMILES
CC1=CC=C(S(NC(NCCCC)=O)(=O)=O)C=C1
InChi Code
InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)
InChi Key
JLRGJRBPOGGCBT-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Tolbutamide is an inhibitor of sulfonylurea receptor 1 (SUR1) linked to ATP-sensitive potassium channel Kir6.2 (IC50 = 4.9 µM).1 It is selective for SUR1/Kir6.2 over SUR2A/Kir6.2 and SUR2B/Kir6.2 channels (IC50s = 85 and 88 µM, respectively). Tolbutamide increases glucose-induced insulin secretion and calcium influx in isolated mouse pancreatic islets.2 In vivo, tolbutamide (80 mg/kg) reduces blood glucose levels in a mouse model of diabetes induced by streptozotocin (STZ; Item No. 13104).3 Formulations containing tolbutamide have been used in the treatment of type 2 diabetes.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Proks, P., Reimann, F., Green, N., et alSulfonylurea stimulation of insulin secretion. Diabetes 51(3), S368-S376 (2002).

    2. Ishiyama, N., Ravier, M.A., and Henquin, J.-C. Dual mechanism of the potentiation by glucose of insulin secretion induced by arginine and tolbutamide in mouse islets. Am. J. Physiol. Endocrinol. Metab. 290(3), E540-E549 (2006).

    3. Rerup, C., and Tarding, F. Streptozotocin- and alloxan-diabetes in mice. Eur. J. Pharmacol. 7(1), 89-96 (1969).